Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (
NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff RoleIf you have suffered a loss on your Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPRNEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Class Action Reminder: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Lead Plaintiff Deadline is September 28, 2026NEW YORK, NY - August 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (
NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kaplan Fox Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Act Before the Lead Plaintiff Deadline on September 28, 2026NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPRNEW YORK, Aug. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff RoleSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (
NASDAQ: CAPR) on behalf of those who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of California and is captioned Darren Ngasseu Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385 (S.D. Cal.). Investors have until September 28, 2026, to file for lead plaintiff status.
Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) – Lead Plaintiff Deadline is September 28, 2026NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (
NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (
NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRNEW ORLEANS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR), if they purchased Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Kaplan Fox Continues to Alert Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Class Action Deadline on September 28, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
